Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC
NCT ID: NCT02474355
Last Updated: 2021-11-11
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
3017 participants
INTERVENTIONAL
2015-09-18
2019-04-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Study site(s) and number of patients planned: Approximately 1500 patients will be recruited in Europe. The recruitment will be increased beyond that as the study will expand in other regions of the world (America, Asia).
Study Design This will be an open-label, single-arm, multinational, multicenter, real world treatment study.
Target patient population: Adult patients (fulfilling the definition of "age of majority" per local regulations) with locally advanced (stage IIIB) or metastatic (stage IV) NSCLC with confirmed T790M mutation, who have received prior EGFR-TKI therapy.
Investigational product (IP), dosage, and mode of administration: AZD9291 is an oral, potent, selective, irreversible inhibitor of both EGFR-TKI sensitising and resistance mutations in NSCLC with a significant selectivity margin over wild-type EGFR. AZD9291 will be administered orally as one 80 mg tablet once a day.
Duration of IP administration: Patients may continue to receive AZD9291 as long as they continue to show clinical benefit, as judged by the investigator, and in the absence of discontinuation criteria). The study will be closed in each participating country as soon as possible following national reimbursement of AZD9291 in that country (up to a max of 90 days post reimbursement). Enrolment will be closed within 6 months after market license approval in that country or at national reimbursement, whichever is sooner. Patients withdrawing from the treatment prior to national reimbursement will be followed up as part of this study. Patients on treatment will receive commercial supply until documented disease progression as per investigator assessment.
In the event that national reimbursement should not be granted following a reasonable time after market license approval in the country, the study will be closed in a maximum period of 18 months after the last patient is enrolled in that country. If applicable, timelines for conversion to commercial drug will be agreed with local bodies which may include regulatory agencies, ethics committees, and institutions. Patient will be followed until death or lost to follow-up.
Study measures: Data collected will include patient demographics, information needed to determine patient eligibility (including medical history, past and current disease characteristics, and tumor EGFR mutational status), AZD9291 exposure, investigator-reported efficacy (including tumor response and disease progression), overall survival (OS), and safety (including serious adverse events \[SAEs\], adverse events leading to dose modification, and adverse events of special interest \[interstitial lung disease/pneumonitis-like events, and QTc prolongation events\]).
Statistical methods: All data will be presented for the overall full analysis/evaluable set, and also by cohorts defined by number and type of previous treatment lines for the advanced disease. Descriptive statistics will be used for all variables, as appropriate. Continuous variables will be summarised by the number of observations, mean, standard deviation, median, minimum, and maximum. Categorical variables will be summarised by frequency counts and percentages for each category. OS and PFS will be summarized using Kaplan-Meier estimates of the median time to death or censoring and quartiles together with their 95% confidence intervals.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AZD9291
Single arm of AZD9291, starting dose of 80mg
T790M+ Testing
If a previous lab report is unavailable, the patient will need to have T790M+ testing.
Baseline Visit Blood & Urine Testing
Blood count and standard chemistry testing to ensure patient meets inclusion/exclusion criteria
Baseline ECG
ECG to ensure absence of any cardiac abnormality
Visual Slit-Lamp Testing
Slit-lamp testing performed to ensure patients do not have any eye abnormalities or symptoms
AZD9291 Dosing
Patients to be provided with AZD9291 every 6 weeks (+/- 7 days)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
T790M+ Testing
If a previous lab report is unavailable, the patient will need to have T790M+ testing.
Baseline Visit Blood & Urine Testing
Blood count and standard chemistry testing to ensure patient meets inclusion/exclusion criteria
Baseline ECG
ECG to ensure absence of any cardiac abnormality
Visual Slit-Lamp Testing
Slit-lamp testing performed to ensure patients do not have any eye abnormalities or symptoms
AZD9291 Dosing
Patients to be provided with AZD9291 every 6 weeks (+/- 7 days)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Adults (according to each country regulations for age of majority)
3. Locally advanced (stage IIIB) or metastatic (stage IV) EGFRm NSCLC, not amenable to curative surgery or radiotherapy, with confirmation of the presence of the T790M mutation
4. Prior therapy with an EGFR-TKI. Patients may have also received additional lines of treatment
5. World Health Organization (WHO) performance status 0-2
6. Adequate bone marrow reserve and organ function as demonstrated by complete blood count, biochemistry in blood and urine at baseline (please refer to IB for guidance)
7. ECG recording at baseline showing absence of any cardiac abnormality as per exclusion criterion #6
8. Female patients of childbearing potential must be using adequate contraceptive measures, must not be breast feeding, and must have a negative pregnancy test prior to start of dosing. Otherwise, they must have evidence of nonchildbearing potential
9. Male patients must be willing to use barrier contraception, i.e., condoms
Exclusion Criteria
2. Patients currently receiving (or unable to stop use at least 1 week prior to receiving the first dose of AZD9291) any treatment known to be potent inhibitors or inducers of cytochrome P450 (CYP) 3A4
3. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension, active bleeding diatheses, active infection including hepatitis B, hepatitis C, and human immunodeficiency virus, or significantly impaired bone marrow reserve or organ function, including hepatic and renal impairment, which in the investigator's opinion would significantly alter the risk/benefit balance.
4. Patient with symptomatic central nervous system (CNS) metastases who is neurologically unstable or has required increasing doses of steroids to manage CNS symptoms within the 2 weeks prior to start AZD9291 administration;
5. Past medical history of ILD, drug-induced ILD, radiation pneumonitis requiring steroid treatment, or any evidence of clinically active ILD
6. Any of the following cardiac criteria:
1. Mean resting corrected QT interval (QTcF) \> 470 ms using Fredericia's formula :
2. Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG (e.g., complete left bundle branch block, third degree heart block, second degree heart block)
3. Any factors that increase the risk of QTc prolongation or risk of arrhythmic events
7. Any unresolved toxicity from prior therapy CTCAE \> grade 3 at the time of starting treatment
8. History of hypersensitivity to excipients of AZD9291 or to drugs with a similar chemical structure or class to AZD9291
18 Years
130 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Parexel
INDUSTRY
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Buenos Aires, , Argentina
Research Site
Buenos Aires, , Argentina
Research Site
CABA, , Argentina
Research Site
Bedford Park, , Australia
Research Site
East Melbourne, , Australia
Research Site
Kurralta Park, , Australia
Research Site
Randwick, , Australia
Research Site
Waratah, , Australia
Research Site
Innsbruck, , Austria
Research Site
Linz, , Austria
Research Site
Salzburg, , Austria
Research Site
Vienna, , Austria
Research Site
Charleroi, , Belgium
Research Site
Edegem, , Belgium
Research Site
Leuven, , Belgium
Research Site
Barretos, , Brazil
Research Site
Belo Horizonte, , Brazil
Research Site
Florianópolis, , Brazil
Research Site
Ijuí, , Brazil
Research Site
Itajaí, , Brazil
Research Site
Porto Alegre, , Brazil
Research Site
Porto Alegre, , Brazil
Research Site
Rio de Janeiro, , Brazil
Research Site
Rio de Janeiro, , Brazil
Research Site
Salvador, , Brazil
Research Site
Salvador, , Brazil
Research Site
São Paulo, , Brazil
Research Site
São Paulo, , Brazil
Research Site
São Paulo, , Brazil
Research Site
Calgary, Alberta, Canada
Research Site
Burnaby, British Columbia, Canada
Research Site
Vancouver, British Columbia, Canada
Research Site
Hamilton, Ontario, Canada
Research Site
North York, Ontario, Canada
Research Site
Oshawa, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Québec, Quebec, Canada
Research Site
Regina, Saskatchewan, , Canada
Research Site
Beijing, , China
Research Site
Beijing, , China
Research Site
Beijing, , China
Research Site
Beijing, , China
Research Site
Beijing, , China
Research Site
Beijing, , China
Research Site
Beijing, , China
Research Site
Beijing, , China
Research Site
Beijing, , China
Research Site
Beijing, , China
Research Site
Changchun, , China
Research Site
Changchun, , China
Research Site
Changsha, , China
Research Site
Chengdu, , China
Research Site
Chongqing, , China
Research Site
Chongqing, , China
Research Site
Chongqing, , China
Research Site
Dalian, , China
Research Site
Fuzhou, , China
Research Site
Fuzhou, , China
Research Site
Fuzhou, , China
Research Site
Guangzhou, , China
Research Site
Guangzhou, , China
Research Site
Guangzhou, , China
Research Site
Haikou, , China
Research Site
Hangzhou, , China
Research Site
Hangzhou, , China
Research Site
Hangzhou, , China
Research Site
Hangzhou, , China
Research Site
Harbin, , China
Research Site
Hefei, , China
Research Site
Hohhot, , China
Research Site
Jinan, , China
Research Site
Kunming, , China
Research Site
Linhai, , China
Research Site
Nanchang, , China
Research Site
Nanjing, , China
Research Site
Nanjing, , China
Research Site
Nanjing, , China
Research Site
Nanjing, , China
Research Site
Nanjing, , China
Research Site
Nanning, , China
Research Site
Nantong, , China
Research Site
Qingdao, , China
Research Site
Shanghai, , China
Research Site
Shanghai, , China
Research Site
Shanghai, , China
Research Site
Shanghai, , China
Research Site
Shenyang, , China
Research Site
Shenyang, , China
Research Site
Shenzhen, , China
Research Site
Shijiahzhuang, , China
Research Site
Tianjin, , China
Research Site
Ürümqi, , China
Research Site
Ürümqi, , China
Research Site
Ürümqi, , China
Research Site
Wuhan, , China
Research Site
Wuhan, , China
Research Site
Wuhan, , China
Research Site
Wuhan, , China
Research Site
Wuxi, , China
Research Site
Xi'an, , China
Research Site
Xi'an, , China
Research Site
Yancheng, , China
Research Site
Yangzhou, , China
Research Site
Yantai, , China
Research Site
Zhengzhou, , China
Research Site
Vejle, , Denmark
Research Site
Dublin, , Ireland
Research Site
Ancona, , Italy
Research Site
Avellino, , Italy
Research Site
Bari, , Italy
Research Site
Bologna, , Italy
Research Site
Brescia, , Italy
Research Site
Cagliari, , Italy
Research Site
Catania, , Italy
Research Site
Florence, , Italy
Research Site
Genova, , Italy
Research Site
Lecce, , Italy
Research Site
Livorno, , Italy
Research Site
Milan, , Italy
Research Site
Napoli, , Italy
Research Site
Novara, , Italy
Research Site
Palermo, , Italy
Research Site
Parma, , Italy
Research Site
Perugia, , Italy
Research Site
Pisa, , Italy
Research Site
Reggio Emilia, , Italy
Research Site
Roma, , Italy
Research Site
Roma, , Italy
Research Site
Roma, , Italy
Research Site
Udine, , Italy
Research Site
Verona, , Italy
Research Site
Dammam, , Saudi Arabia
Research Site
Riyadh, , Saudi Arabia
Research Site
Anyang, , South Korea
Research Site
Busan, , South Korea
Research Site
Busan, , South Korea
Research Site
Busan, , South Korea
Research Site
Cheongju-si, , South Korea
Research Site
Daegu, , South Korea
Research Site
Daegu, , South Korea
Research Site
Daejeon, , South Korea
Research Site
Gangneung-si, , South Korea
Research Site
Goyang-si, , South Korea
Research Site
Incheon, , South Korea
Research Site
Jeonju, , South Korea
Research Site
Jeonnam, , South Korea
Research Site
JinJoo, , South Korea
Research Site
Seogu, , South Korea
Research Site
Seongnam-si, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
Suwon, , South Korea
Research Site
Ulsan, , South Korea
Research Site
A Coruña, , Spain
Research Site
Alicante, , Spain
Research Site
Badalona, , Spain
Research Site
Barcelona, , Spain
Research Site
Castellon, , Spain
Research Site
Donostia / San Sebastian, , Spain
Research Site
Jaén, , Spain
Research Site
Las Palmas de Gran Canaria, , Spain
Research Site
León, , Spain
Research Site
Madrid, , Spain
Research Site
Madrid, , Spain
Research Site
Majadahonda, , Spain
Research Site
Oviedo, , Spain
Research Site
Palma de Mallorca, , Spain
Research Site
Seville, , Spain
Research Site
Valencia, , Spain
Research Site
Valencia, , Spain
Research Site
Zaragoza, , Spain
Research Site
Örebro, , Sweden
Research Site
Uppsala, , Sweden
Research Site
Kaohsiung City, , Taiwan
Research Site
Kaohsiung City, , Taiwan
Research Site
Taichung, , Taiwan
Research Site
Tainan City, , Taiwan
Research Site
Taipei, , Taiwan
Research Site
Taipei, , Taiwan
Research Site
Taipei, , Taiwan
Research Site
Taoyuan District, , Taiwan
Research Site
Antrim, , United Kingdom
Research Site
London, , United Kingdom
Research Site
London, , United Kingdom
Research Site
Norwich, , United Kingdom
Research Site
Poole, , United Kingdom
Research Site
Wolverhampton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Zhou Q, Zhang HL, Jiang LY, Shi YK, Chen Y, Yu JM, Zhou CC, He Y, Hu YP, Liang ZA, Pan YY, Zhuo WL, Song Y, Wu G, Chen GY, Lu Y, Zhang CY, Zhang YP, Cheng Y, Lu S, Wang CL, Zhou JY, Liu YP, He JX, Wang J, Wu YL. Real-world evidence of osimertinib in Chinese patients with EGFR T790M-positive non-small cell lung cancer: a subgroup analysis from ASTRIS study. J Cancer Res Clin Oncol. 2023 Sep;149(12):10771-10780. doi: 10.1007/s00432-023-04923-8. Epub 2023 Jun 14.
Cheema P, Cho BC, Freitas H, Provencio M, Chen YM, Kim SW, Wu YL, Passaro A, Martin C, Tiseo M, Chang GC, Park K, Solomon B, Burghuber O, Laskin J, Wang Z, Lee SY, Hu Y, Vansteenkiste J, Zhang HL, Hanrahan E, Geldart T, Taylor R, Servidio L, Li J, Marinis F. A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data. Future Oncol. 2023 Jan;19(1):61-75. doi: 10.2217/fon-2022-0919. Epub 2023 Jan 19.
Leighl NB, Kamel-Reid S, Cheema PK, Laskin J, Karsan A, Zhang T, Stockley T, Barnes TA, Tudor RA, Liu G, Owen S, Rothenstein J, Burkes RL, Iqbal M, Spatz A, van Kempen LC, Izevbaye I, Laurence D, Le LW, Tsao MS. Multicenter Validation Study to Implement Plasma Epidermal Growth Factor Receptor T790M Testing in Clinical Laboratories. JCO Precis Oncol. 2020 Nov;4:520-533. doi: 10.1200/PO.19.00335.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
D5160C00022 Clinical Study Protocol
D5160C00022 Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D5160C00022
Identifier Type: -
Identifier Source: org_study_id